Reducing the levels of the protein NEK2 in the pulmonary arteries lessened disease-driving changes in blood vessels and the heart of a rat model of pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD). The effects were tied to a modulation of the NF-kB pathway involved in vascular…
Read more
Synhale Therapeutics has acquired the rights to the experimental therapy telaglenastat (CB-839), which has previously been tested as a potential cancer therapy. The company is planning to launch a Phase 2 clinical trial to test telaglenastat in people with pulmonary hypertension (PH). “This acquisition represents a unique opportunity to…
Hospital rounds are usually morning visits from a patient’s healthcare team to review their condition, treatment plan, and progress. The patient is examined, vitals are checked, and additional tests are ordered if needed. Tests can range from blood work or imaging to more invasive procedures such as cardiac catheterization. Depending…
Get regular updates to your inbox.
